Table 1.
Clinical characteristics of patients with CR1 and not CR
| ID | CR1 (n=791) | Not CR (n=249) | X2 | P-value |
|---|---|---|---|---|
| Age | 2.969 | 0.085 | ||
| <14 | 549 (69.4%) | 187 (75.1%) | ||
| ≥14 | 242 (30.6%) | 62 (24.9%) | ||
| Gender | 0.609 | 0.435 | ||
| Male | 416 (52.6%) | 138 (55.4%) | ||
| Female | 375 (47.4%) | 111 (44.6%) | ||
| White blood cell | 4.567 | 0.033 | ||
| <150 | 720 (91%) | 215 (86.3%) | ||
| ≥150 | 71 (9%) | 34 (13.7%) | ||
| Bone marrow leukemic blast | 0.386 | 0.534 | ||
| <90% | 603 (76.2%) | 185 (74.3%) | ||
| ≥90% | 188 (23.8%) | 64 (25.7%) | ||
| Peripheral blasts | 1.657 | 0.198 | ||
| <90% | 715 (90.4%) | 218 (87.6%) | ||
| ≥90% | 76 (9.6%) | 31 (12.4%) | ||
| CNS disease | 2.560 | 0.110 | ||
| Yes | 47 (5.9%) | 22 (8.8%) | ||
| No | 744 (94.1%) | 227 (91.2%) | ||
| Chloroma | 4.110 | 0.043 | ||
| Yes | 86 (10.9%) | 39 (15.7%) | ||
| No | 705 (89.1%) | 210 (84.3%) | ||
| FAB category | 24.741 | 0.001 | ||
| MO | 16 (2%) | 15 (6%) | ||
| M1 | 86 (10.9%) | 33 (13.3%) | ||
| M2 | 178 (22.5%) | 52 (20.9%) | ||
| M3 | 2 (0.3%) | 0 (0%) | ||
| M4 | 192 (24.3%) | 33 (13.3%) | ||
| M5 | 148 (18.7%) | 46 (18.5%) | ||
| M6 | 13 (1.6%) | 4 (1.6%) | ||
| M7 | 31 (3.9%) | 15 (6%) | ||
| Unknown | 125 (15.8%) | 51 (20.5%) | ||
| Primary cytogenetic code | 25.819 | <0.001 | ||
| inv (16) | 115 (14.5%) | 12 (4.8%) | ||
| MLL | 146 (18.5%) | 44 (17.7%) | ||
| t (8;21) | 123 (15.5%) | 29 (11.6%) | ||
| Other | 189 (23.9%) | 85 (34.1%) | ||
| Normal | 180 (22.8%) | 68 (27.3%) | ||
| Unknown | 38 (4.8%) | 11 (4.4%) | ||
| FLT3/ITD positive | 7.974 | 0.005 | ||
| Yes | 133 (16.8%) | 62(24.9%) | ||
| No | 655 (82.8%) | 187(75.1%) | ||
| Unknown | 3 (0.4%) | 0 (0%) | ||
| FLT3 PM | 0.057 | 0.811 | ||
| Yes | 54 (6.8%) | 16 (6.4%) | ||
| No | 733 (92.7%) | 233 (93.6%) | ||
| Unknown | 4 (0.5%) | 0 (0%) | ||
| NPM mutation | 5.225 | 0.022 | ||
| Yes | 77 (9.7%) | 13 (5.2%) | ||
| No | 698 (88.2%) | 236 (94.8%) | ||
| Unknown | 16 (2%) | 0 (0%) | ||
| CEBPA mutation | 5.156 | 0.023 | ||
| Yes | 52 (6.6%) | 7 (2.8%) | ||
| No | 727 (91.9%) | 241 (96.8%) | ||
| Unknown | 12 (1.5%) | 1 (0.4%) | ||
| WT1 mutation | 12.147 | <0.001 | ||
| Yes | 45 (5.7%) | 31(12.4%) | ||
| No | 731 (92.4%) | 218(87.6%) | ||
| Unknown | 15 (1.9%) | 0 (0%) | ||
| c-Kit mutation exon 8 | 0.457 | 0.499 | ||
| Yes | 36 (4.6%) | 5 (2%) | ||
| No | 189 (23.9%) | 37 (14.9%) | ||
| Not done | 566 (71.6%) | 207 (83.1%) | ||
| c-Kit mutation exon 17 | 2.321 | 0.128 | ||
| Yes | 24 (3%) | 8 (3.2%) | ||
| No | 200 (25.3%) | 34(13.7%) | ||
| Not done | 567 (71.7%) | 207 (83.1%) | ||
| MRD at end of course 1 | 161.121 | <0.001 | ||
| Yes | 126 (15.9%) | 143 (57.4%) | ||
| No | 492 (62.2%) | 68 (27.3%) | ||
| Unknown | 173 (21.9%) | 38 (15.3%) | ||
Abbreviations: CR, complete remission; FAB, French-American-British; MRD, minimal residual disease.